SHELTON,
Conn., Nov. 8, 2024 /PRNewswire/ -- Intensity
Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a
late-stage clinical biotechnology company focused on the discovery
and development of proprietary, novel immune-based intratumorally
injected cancer therapies intended to kill tumors directly and
increase immune system recognition of cancers, today announced
that its Phase 3 trial has been selected for an oral podium
presentation at the 2024 Connective Tissue Oncology Society (CTOS)
on November 16, 2024. Dr.
Christian F. Meyer MD, Ph.D will be
making the oral presentation highlighting completed Phase 2 results
and the INVINCIBLE-3 (Phase 3) randomized soft tissue sarcoma trial
design and important study criteria. The annual CTOS conference
runs from November 13 to 16, 2024 in
San Diego at the Grand Hyatt.
Presentation Details
Session 11: Trials in
Progress/Late Breaking Trials
Moderator: Palma Dileo,
MD (she/her/hers) – University College London Hospitals NHS
Foundation Trust
Moderator: Steven I.
Robinson, M.B.B.S. (he/him/his) – Mayo Clinic
Paper 78 - A MULTICENTER, RANDOMIZED, PHASE 3 STUDY OF
INTRATUMORAL INT230-6 (SHAO, VINBLASTINE, CISPLATIN) COMPARED TO
STANDARD OF CARE THERAPY IN SELECTED METASTATIC SOFT TISSUE
SARCOMAS: INVINCIBLE-3 TRIAL.
Date: Saturday, November 16,
2024
Time: 9:00 AM PST
Location: Harbor Ballroom
Author: Albiruni Abdul Razak, MB BCh, BAO, LRCP & SI –
Toronto Sarcoma Program, Princess Margaret Cancer Center
Presenter: Christian F.
Meyer, MD PhD (he/him/his) – Johns
Hopkins University
About Intensity Therapeutics
Intensity Therapeutics is a late-stage clinical biotechnology
company that applies novel engineered chemistry by enabling its
aqueous cytotoxic-containing drug product, INT230-6, to mix and
saturate the tumor's dense, high-fat pressurized environment. As a
result of the saturation, Intensity's clinical trials have
demonstrated the ability of INT230-6 to kill tumors and elicit an
adaptive immune response within days of injection, representing a
novel approach to cancer cell death that holds the potential to
shift the treatment paradigm and turn many deadly cancers into
chronic diseases even for cancers that do not respond to
immunotherapy. Intensity complete two large clinical studies using
INT230-6 that enrolled over 200 patients: a Phase 1/2 dose
escalation trial (NCT03058289) and a Phase 2 randomized control
clinical trial in breast cancer (the INVINCIBLE-2 study)
(NCT04781725). Intensity Therapeutics initiated a Phase 3
trial in soft tissue sarcoma (the INVINCIBLE-3 study)
(NCT06263231), testing INT230-6 as second or third-line monotherapy
compared to the standard of care with overall survival as an
endpoint. The Company is also conducting a Phase 2 study in
collaboration with The Swiss Group for Clinical Cancer Research
SAKK as part of a Phase 2/3 program evaluating INT230-6 followed by
SOC and SOC alone for patients with presurgical triple-negative
breast cancer. Information on the Phase 2 portion of the program
(INVINCIBLE-4 Study) is listed under (NCT06358573). For more
information about the Company, including publications, papers and
posters about its novel approach to cancer therapeutics,
visit www.intensitytherapeutics.com.
About the Connective Tissue Oncology Society and
Sarcoma
The Connective Tissue Oncology Society was formed in 1995 and
incorporated in 1997. CTOS is an international group comprised of
physicians and scientists with a primary interest in the tumors of
connective tissues such as soft tissue sarcomas, which are a rare
type of cancer that develops in the soft tissues of the body, such
as muscle, fat, blood vessels, and nerves: The goal of the society
is to advance the care of patients with connective tissue tumors
and to increase knowledge of all aspects of the biology of these
tumors, including basic and clinical research.
Forward-Looking Statements
Certain statements in this press release may constitute
"forward-looking statements" within the meaning of the United
States Private Securities Litigation Reform Act of 1995, as amended
to date. These statements include but are not limited to,
statements relating to the development of the Company's clinical
programs. When or if used in this communication, the words "may,"
"could," "should," "anticipate," "believe," "estimate," "expect,"
"intend," "plan," "predict" and similar expressions and their
variants, as they relate to the Company or its management, may
identify forward-looking statements. The forward-looking statements
contained in this press release are based on management's current
expectations and projections about future events. Nevertheless,
actual results or events could differ materially from the plans,
intentions, and expectations disclosed in, or implied by, the
forward-looking statements. These risks and uncertainties, many of
which are beyond our control, include: the initiation, timing,
progress and results of future preclinical studies and clinical
trials and research and development programs; the need to raise
additional funding before the Company can expect to generate any
revenues from product sales; plans to develop and commercialize
product candidates; the timing or likelihood of regulatory filings
and approvals; the ability of the Company's research to generate
and advance additional product candidates; the implementation of
the Company's business model, strategic plans for the Company's
business, product candidates and technology; commercialization,
marketing and manufacturing capabilities and strategy; the rate and
degree of market acceptance and clinical utility of the Company's
system; the Company's competitive position; the Company's
intellectual property position; developments and projections
relating to the Company's competitors and its industry; the
Company's ability to maintain and establish collaborations or
obtain additional funding; expectations related to the use of cash
and cash equivalents and investments; estimates regarding expenses,
future revenue, capital requirements and needs for additional
financing; and other risks described in the section entitled "Risk
Factors" in the Company's SEC filings, which can be obtained on the
SEC website at www.sec.gov. Readers are cautioned not to place
undue reliance on the forward-looking statements, which speak only
as of the date on which they are made and reflect management's
current estimates, projections, expectations and beliefs. The
Company does not plan to update any such forward-looking statements
and expressly disclaims any duty to update the information
contained in this press release except as required by law.
Investor Relations Contact:
Justin Kulik
Justin@coreir.com
CORE IR
(516) 222-2560
Media Contact:
Jules
Abraham
CORE IR
pr@coreir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/intensity-therapeutics-selected-for-oral-podium-presentation-in-a-late-breaking-session-at-the-2024-annual-connective-tissue-oncology-society-sarcomas-meeting-302296991.html
SOURCE Intensity Therapeutics Inc.
